Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Hai Yi
Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study
Abstract Chronic graft-versus-host disease (cGVHD) remains a major complication following allogeneic hematopoietic stem cell transplantation for long-term survival. Emerging evidence highlights Rho-associated coiled-coil kinase 2 (ROCK2) as a promising therapeutic target for cGVHD, which can modulate immune responses and profibrotic reactions. TDI01, a potent and highly selective ROCK2 inhibitor, represents a potential breakthrough in cGVHD treatment.
Poor platelet engraftment combined with persistent pulmonary infection after haploidentical allogeneic hematopoietic stem cell transplantation: a case report
Abstract Poor graft function (PGF) with persistent thrombocytopenia is a serious post-transplant complication linked to increased mortality. Active infections can worsen outcomes. We report a case of secondary poor platelet engraftment with refractory pulmonary infection after haploidentical HSCT. A 52-year-old woman developed Rhizopus microsporus infection on day +1. Neutrophil engraftment occurred by day +13, but platelet engraftment was delayed until day +40.
Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis - Bone Marrow Transplantation
Abstract Graft failure (GF) is a barrier to successful allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelofibrosis (MF). We investigated the incidence, risk factors, and prognosis for GF after allo-HSCT for MF. Two hundred and eleven patients with MF who underwent allo-HSCT across 32 hematology centers in China between December 2008 and December 2024 were retrospectively analyzed.
A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity
Keywords T cell malignancies CD5 natural killer cells CD16a nanobody immunotherapy Introduction The overall prognosis of patients with T cell malignancies, a heterogeneous group of diseases with high rates of recurrence and mortality, is generally poor, particularly when compared to that of patients with B cell malignancies.1 Although current strategies such as chemotherapy have been beneficial for certain disease subsets, their effectiveness in patients with relapsed or refractory diseases...
Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ajh27746-sup-0001-Supinfo.docxWord 2007 document , 669.1 KB Data S1. Supporting Information. References 1, , , et al., “Hematopoietic Stem Cell Transplantation Activity in China 2019: A Report From the Chinese Blood and Marrow Transplantation Registry Group,” Bone Marrow Transplantation 56 (2021): 2940–2947.
Clinical outcomes of offspring and matched unrelated donor transplants in relapsed or refractory severe aplastic anemia patients aged 40-50: a retrospective analysis from the CBMTR over the past decade | Bone Marrow Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the sole curative treatment for severe aplastic anemia (SAA) [1]. When immunosuppressive therapy fails and a matched sibling donor (MSD) is unavailable, alternative donor transplantation (ADT) is recommended for SAA patients under 50 years old [1]. However, searching and identifying a suitable matched unrelated donor (MUD) for transplantation is a time-consuming process, typically taking three to six months [2].
Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia With Active Left Neck Tuberculosis: A Case Report
Please review our Terms and Conditions of Use and check box below to share full-text version of article. I have read and accept the Wiley Online Library Terms and Conditions of Use Use the link below to share a full-text version of this article with your friends and colleagues. Learn more.
A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study | Bone Marrow Transplantation
Abstract Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy and the only curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT is not appropriate for all CMML patients, and relapse is the leading cause of treatment failure. This project conducted a nationwide multicenter real-world study to develop a novel prediction scoring system for early relapse.
Bibliometric Analysis of Studies on the lipid management of coronary heart disease from 2014 to 2023
SYSTEMATIC REVIEW article Front. Cardiovasc. Med. Sec.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Hai
Contact Hai, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack